darolutamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
non-steroid antiandrogens 5334 1297538-32-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • darolutamide
  • nubeqa
  • BAY 1841788
  • ODM-201
Darolutamide is an androgen receptor (AR) inhibitor. Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR-mediated transcription. A major metabolite, keto-darolutamide, exhibited similar in vitro activity to darolutamide. In addition, darolutamide functioned as a progesterone receptor (PR) antagonist in vitro (approximately 1% activity compared to AR). Darolutamide decreased prostate cancer cell proliferation in vitro and tumor volume in mouse xenograft models of prostate cancer
  • Molecular weight: 398.85
  • Formula: C19H19ClN6O2
  • CLOGP: 1.98
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 3
  • TPSA: 119.62
  • ALOGS: -3.74
  • ROTB: 6
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.20 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 27, 2020 EMA Bayer AG
July 30, 2019 FDA BAYER HEALTHCARE PHARMACEUTICALS INC
Jan. 23, 2020 PMDA Bayer Yakuhin, Ltd

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 61.29 38.31 16 295 12548 29561668
Fatigue 42.76 38.31 31 280 316790 29257426

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Prostatic specific antigen increased 43.55 36.65 9 189 8751 64489783
Fatigue 38.34 36.65 25 173 748705 63749829

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BB06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Anti-androgens

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hormone refractory prostate cancer indication 427492003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.99 acidic
pKa2 12.59 acidic
pKa3 1.18 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
300MG NUBEQA BAYER HEALTHCARE N212099 July 30, 2019 RX TABLET ORAL 8975254 Oct. 27, 2030 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
300MG NUBEQA BAYER HEALTHCARE N212099 July 30, 2019 RX TABLET ORAL 9657003 Oct. 27, 2030 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
300MG NUBEQA BAYER HEALTHCARE N212099 July 30, 2019 RX TABLET ORAL 10835515 Jan. 28, 2036 TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
300MG NUBEQA BAYER HEALTHCARE N212099 July 30, 2019 RX TABLET ORAL July 30, 2024 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor INHIBITOR IC50 7.19 SCIENTIFIC LITERATURE DRUG LABEL
Progesterone receptor Nuclear hormone receptor ANTAGONIST DRUG LABEL
Androgen receptor Transcription factor ANTAGONIST Ki 7.96 IUPHAR

External reference:

IDSource
X05U0N2RCO UNII
C4547776 UMLSCUI
CHEMBL4297185 ChEMBL_ID
67171867 PUBCHEM_CID
DB12941 DRUGBANK_ID
D11045 KEGG_DRUG
10439 IUPHAR_LIGAND_ID
2180325 RXNORM
321167 MMSL
37249 MMSL
d09337 MMSL
789148001 SNOMEDCT_US
789166006 SNOMEDCT_US
4038612 VANDF
018070 NDDF
C000607739 MESH_SUPPLEMENTAL_RECORD_UI
10227 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NUBEQA HUMAN PRESCRIPTION DRUG LABEL 1 50419-395 TABLET, FILM COATED 300 mg ORAL NDA 28 sections